BMS to Present P-III Study (COMMANDS) of Reblozyl (luspatercept-aamt) as 1L Treatment of Anemia in Adults with Lower-Risk MDS at ASCO and EHA 2023
Shots:
- The P-III study evaluating Reblozyl vs epoetin alfa for anemia in 363 adult patients with very low, low, or intermediate-risk MDS who require RBC transfusions & are ESA-naïve with median treatment durations of 41.6 & 27wks.
- 58.5% vs 31.2% achieved the 1EPs of RBC-TI of 12wks. with Hb increase of 1.5g/dL within the first 24wks.; HI-E increase (74.1% vs 51.3%) @8wks. along with more durable responses with a m-DoR of RBC-TI ≥12wks. (126.6 vs 77wks.); RBC-TI (47.6% vs 29.2%) within the first 24wks., Benefits were observed in clinically relevant subgroups and showed a consistent safety profile with no new safety signals
- The sBLA of Reblozyl is currently under the US FDA's Priority Review for the same indication & the PDUFA date is expected in Aug 2023
Ref: BMS | Image: BMS
Related News:- BMS Reports P-II Study Results of BMS-986278 for the Treatment of Idiopathic Pulmonary Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
